NHS England Backs Biosimilar-To-Biosimilar Switching As It Counts Adalimumab Savings
• By Aidan Fry
Multiple switches between biosimilars do not raise safety concerns. NHS England has stated in a briefing document on adalimumab • Source: Shutterstock 
